On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Dr. Glick (Dermatologist) and Dr. Sulich (Rheumatologist) discuss recognizing early signs of psoriatic arthritis in your patients, and the importance of communication between specialties for the successful comanagement of patients.
Explore Otezla data from the ESTEEM trials in moderate to severe plaque psoriasis and the PALACE trials in active psoriatic arthritis.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations